The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Cited by
Sorted by citations
Items 801–900 of 1,085
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 186
Hendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., Curigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253654 · Cited by 183
Lv, C., Li, F., Li, X., Tian, Y., Zhang, Y., Sheng, X., Song, Y., Meng, Q., Yuan, S., Luan, L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01059-5 · Cited by 184
Boggs, A. E., Vitolo, M. I., Whipple, R. A., Charpentier, M. S., Goloubeva, O. G., Ioffe, O. B., Tuttle, K. C., Slovic, J., Lu, Y., Mills, G. B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3563 · Cited by 181
McDonald, K.-A., Kawaguchi, T., Qi, Q., Peng, X., Asaoka, M., Young, J. S., Opyrchal, M., Yan, L., Patnaik, S. K., Otsuji, E., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07338-3 · Cited by 184
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Telonis, A. G., Loher, P., Honda, S., Jing, Y., Palazzo, J., Kirino, Y., & Rigoutsos, I. (2015) · Oncotarget · doi:10.18632/oncotarget.4695 · Cited by 191
Czerniak, B. A., Dinney, C. P., & McConkey, D. J. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104703 · Cited by 182
The PGC-1/ERR signaling axis in cancer
Deblois, G., St‐Pierre, J., & Giguère, V. (2012) · Oncogene · doi:10.1038/onc.2012.529 · Cited by 180
Martín, M., Chan, A., Dirix, L. Y., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M. I., Криворотько, П. В., López, N. B., Campone, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 183
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Siegel, M. B., He, X., Hoadley, K. A., Hoyle, A. P., Pearce, J. B., Garrett, A., Kumar, S., Moylan, V. J., Brady, C., Swearingen, A. E. D. V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96153 · Cited by 186
Wu, H., Lin, J., Liu, Y.-E., Chen, H., Hsu, K., Lin, S.-H., Peng, K., Lin, K.-J., Hsieh, C., & Chen, D. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153437 · Cited by 181
Aftimos, P. G., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C. P., Gal‐Yam, E. N., Robson, M. E., Ndozeng, J., Leo, A. D., Ciruelos, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1647 · Cited by 180
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E. M., Wicinski, J., Devouassoux‐Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 189
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Yu, T., & Di, G. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.03.10 · Cited by 184
The Spectrum of Triple-Negative Breast Disease
Geyer, F. C., Pareja, F. G., Weigelt, B., Rakha, E. A., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.03.016 · Cited by 189
Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer
Stutheit-Zhao, E. Y., Shen, Y., Pleasance, E., Kasaian, K., Leelakumari, S., Jones, M. R., Bose, P., Ch’ng, C., Reisle, C., Eirew, P. D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1941 · Cited by 179
Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1337 · Cited by 182
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 182
CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer
Kemp, C. J., Moore, J. M., Moser, R. D., Bernard, B. M., Teater, M. R., Smith, L. E., Rabaia, N. A., Gurley, K. E., Guinney, J., Busch, S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.004 · Cited by 178
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen‐Dale, A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 178
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhäuser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 182
Xu, X., Zhang, L., He, X., Zhang, P., Sun, C., Xu, X., Lu, Y., & Li, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.139 · Cited by 178
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2018) · Cancer Science · doi:10.1111/cas.13837 · Cited by 183
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
A novel approach for data integration and disease subtypingPreprint
Nguyen, T., Tagett, R., Diaz, D., & Drăghici, S. (2017) · Genome Research · doi:10.1101/gr.215129.116 · Cited by 183
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 181
TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein
Bhatnagar, S., Gazin, C., Chamberlain, L., Ou, J., Zhu, X., Tushir, J. S., Virbasius, C.-M. A., Lin, L., Zhu, L. J., Wajapeyee, N., et al. (2014) · Nature · doi:10.1038/nature13955 · Cited by 177
Three-stage quality control strategies for DNA re-sequencing data
Guo, Y. P., Ye, F., Sheng, Q., Clark, T. A., & Samuels, D. C. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbt069 · Cited by 177
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 184
Wu, P., Heins, Z., Muller, J., Katsnelson, L., de Bruijn, I., Abeshouse, A. A., Schultz, N. D., Fenyö, D., & Gao, J. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001673 · Cited by 179
Costa, R. L. B., Shah, A. N., Santa-Maria, C. A., Cruz, M. R. D. S., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.010 · Cited by 177
Triple negative breast cancer in Asia: An insider’s view
Wang, C., Kar, S., Lai, X., Cai, W., Arfuso, F., Sethi, G., Lobie, P. E., Goh, B. C., Lim, L. H. K., Hartman, M., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.014 · Cited by 176
Sarmiento-Salinas, F. L., Delgado-Magallón, A., Montes-Alvarado, J. B., Ramírez-Ramírez, D., Flores-Alonso, J. C., Cortés-Hernández, P., Reyes‐Leyva, J., Camacho, I. H., Anaya-Ruı́z, M., Pelayo, R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00480 · Cited by 180
Angelis, M. L. D., Francescangeli, F., & Zeuner, A. (2019) · Cancers · doi:10.3390/cancers11101569 · Cited by 180
Karim, A. M., Kwon, J. E., Ali, T., Jang, J., Ullah, I., Lee, Y., Park, D. W., Park, J. H., Jeang, J. W., & Kang, S. C. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115545 · Cited by 182
Telonis, A. G., Loher, P., Yi, J., Londin, E. R., & Rigoutsos, I. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv922 · Cited by 179
Genetic alterations of histone lysine methyltransferases and their significance in breast cancer
Liu, L., Kimball, S., Liu, H., Holowatyj, A., & Yang, Z.-Q. (2014) · Oncotarget · doi:10.18632/oncotarget.2967 · Cited by 178
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Maguire, S. L., Leonidou, A., Wai, P. T., Marchiò, C., Ng, C. K. Y., Sapino, A., Vincent‐Salomon, A., Reis-Filho, J. S., Weigelt, B., & Natrajan, R. (2014) · The Journal of Pathology · doi:10.1002/path.4483 · Cited by 178
Cancer Systems Biology: a peek into the future of patient care?
Werner, H. M. J., Mills, G. B., & Ram, P. T. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.6 · Cited by 178
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
Mattos‐Arruda, L. D., Cortés, J., Santarpia, L., Vivancos, A. P., Tabernero, J. M., Reis-Filho, J. S., & Seoane, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.80 · Cited by 176
Han, L., Yuan, Y., Zheng, S., Yang, Y., Li, J., Edgerton, M. E., Diao, L., Xu, Y., Verhaak, R. G. W., & Liang, H. (2014) · Nature Communications · doi:10.1038/ncomms4963 · Cited by 179
Genome-wide DNA methylation profiles in progression to
Fleischer, T., Frigessi, A., Johnson, K. C., Edvardsen, H., Touleimat, N., Klajic, J., Riis, M. L. H., Haakensen, V. D., Wärnberg, F., Naume, B., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0435-x · Cited by 175
FOXC1: an emerging marker and therapeutic target for cancer
Han, B., Bhowmick, N. A., Qu, Y., Chung, S., Giuliano, A. E., & Cui, X. (2017) · Oncogene · doi:10.1038/onc.2017.48 · Cited by 184
Polycarpou‐Schwarz, M., Groß, M., Mestdagh, P., Schott, J., Grund, S. E., Hildenbrand, C., Rom, J., Aulmann, S., Sinn, H., Vandesompele, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0281-5 · Cited by 175
Re-definition of claudin-low as a breast cancer phenotype
Fougner, C., Bergholtz, H., Norum, J. H., & Sørlie, T. (2020) · Nature Communications · doi:10.1038/s41467-020-15574-5 · Cited by 175
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174
Inferring biological tasks using Pareto analysis of high-dimensional data
Hart, Y., Sheftel, H., Hausser, J., Székely, P., Moshe, N. B. B., Kohanim, Y. K., Tendler, A., Mayo, A., & Alon, U. S. (2015) · Nature Methods · doi:10.1038/nmeth.3254 · Cited by 174
ABRA: improved coding indel detection via assembly-based realignment
Mose, L. E., Wilkerson, M. D., Hayes, D. N., Perou, C. M., & Parker, J. S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu376 · Cited by 178
Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities
Dieci, M. V., Orvieto, E., Dominici, M., Conte, P., & Guarneri, V. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0108 · Cited by 174
dos Santos, A. F., Terra, L. F., Wailemann, R. A. M., Oliveira, T. C., Gomes, V. M., Mineiro, M. F., Meotti, F. C., Bruni‐Cardoso, A., Baptista, M. S., & Labriola, L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3179-7 · Cited by 181
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors
Lim, K. S., Li, H., Roberts, E. A., Gaudiano, E. F., Clairmont, C. S., Sambel, L. A., Ponnienselvan, K., Liu, J., Yang, C., Kozono, D., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.045 · Cited by 174
Won, H. S., Ahn, J., Kim, Y., Kim, J. S., Song, J.-Y., Kim, H., Lee, J., Park, H. K., & Kim, Y. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01519-x · Cited by 175
Lightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
Sebestyén, E., Zawisza-Álvarez, M., & Eyras, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1392 · Cited by 185
Cuiffo, B., Campagne, A., Bell, G. W., Lembo, A., Orso, F., Lien, E. C., Bhasin, M., Raimo, M., Hanson, S. E., Marusyk, A., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.001 · Cited by 175
Chen, W.-C., Wang, C., Hung, Y.-H., Weng, T., Yen, M., & Lai, M.-D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155660 · Cited by 173
RANKL/RANK control Brca1 mutation-driven mammary tumors
Sigl, V., Owusu-Boaitey, K. E., Joshi, P. A., Kavirayani, A. M., Wirnsberger, G., Novatchkova, M., Kozieradzki, I., Schramek, D., Edokobi, N., Hersl, J., et al. (2016) · Cell Research · doi:10.1038/cr.2016.69 · Cited by 175
Molecular characterization and targeted therapeutic approaches in breast cancer
Toss, A., & Cristofanilli, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0560-9 · Cited by 179
Kwak, E. L., Ahronian, L. G., Siravegna, G., Mussolin, B., Borger, D. R., Godfrey, J. T., Jessop, N. A., Clark, J. W., Blaszkowsky, L. S., Ryan, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0748 · Cited by 175
Brain metastasis: Unique challenges and open opportunities
Lowery, F. J., & Yu, D. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.12.001 · Cited by 177
Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
Gevensleben, H., García-Murillas, I., Graeser, M., Schiavon, G., Osin, P., Parton, M., Smith, I. E., Ashworth, A., & Turner, N. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3768 · Cited by 174
Brooks, A. N., Choi, P. S., de Waal, L. M., Sharifnia, T., Imielinski, M. B., Saksena, G., Pedamallu, C. S., Sivachenko, A., Rosenberg, M. W., Chmielecki, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087361 · Cited by 173
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C. S. F., Momčilović, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4213 · Cited by 171
Brufsky, A., & Dickler, M. N. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0423 · Cited by 179
Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
Neophytou, C. M., Boutsikos, P., & Papageorgis, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00031 · Cited by 175
Zhu, Y., Liu, Y., Zhang, C., Chu, J., Wu, Y., Li, Y., Liu, J., Li, Q., Li, S., Shi, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03951-0 · Cited by 171
Genetic determinants of cellular addiction to DNA polymerase theta
Feng, W., Simpson, D. A., Carvajal-Garcia, J., Price, B. A., Kumar, R. J., Mose, L. E., Wood, R. D., Rashid, N. U., Purvis, J. E., Parker, J. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12234-1 · Cited by 171
Mao, P., Cohen, O., Kowalski, K. J., Kusiel, J. G., Buendia-Buendia, J. E., Cuoco, M. S., Exman, P., Wander, S. A., Waks, A. G., Nayar, U., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3958 · Cited by 171
An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 171
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 175
The thioredoxin system in breast cancer cell invasion and migration
Bhatia, M., McGrath, K. L., Trapani, G. D., Charoentong, P., Shah, F., King, M. M., Clarke, F. M., & Tonissen, K. F. (2015) · Redox Biology · doi:10.1016/j.redox.2015.12.004 · Cited by 170
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Chen, L., Liu, Y., Yao, L., Kuang, X.-Y., Zuo, W., Li, S., Qiao, F., Liu, Y., Cao, Z.-G., Zhou, S.-L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03867-9 · Cited by 170
USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer
Pan, J., Deng, Q., Jiang, C., Wang, X., Niu, T., Li, H., Chen, T., Jin, J., Pan, W., Cai, X., et al. (2014) · Oncogene · doi:10.1038/onc.2014.327 · Cited by 169
Akbani, R., Becker, K., Carragher, N. O., Goldstein, T., de Koning, L., Korf, U., Liotta, L. A., Mills, G. B., Nishizuka, S., Pawlak, M., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o113.034918 · Cited by 172
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
Dogruluk, T., Tsang, Y. H., Espitia, M., Chen, F., Chen, T., Chong, Z., Appadurai, V., Dogruluk, A., Eterovic, K. A., Bonnen, P. E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1654 · Cited by 169
Michaut, M., Chin, S., Majewski, I. J., Severson, T., Bismeijer, T., de Koning, L., Peeters, J. K., Schouten, P. C., Rueda, O. M., Bosma, A. J., et al. (2016) · Scientific Reports · doi:10.1038/srep18517 · Cited by 174
PureCN: copy number calling and SNV classification using targeted short read sequencing
Riester, M., Singh, A., Brannon, A. R., Yu, K., Campbell, C. D., Chiang, D. Y., & Morrissey, M. (2016) · Source Code for Biology and Medicine · doi:10.1186/s13029-016-0060-z · Cited by 169
Fribbens, C. V., García-Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 171
Glucose Metabolism and Glucose Transporters in Breast Cancer
Shin, E., & Koo, J. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728759 · Cited by 172
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Leo, A. D. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.99 · Cited by 170
Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Speers, C. W., Zhao, S., Liu, M., Bartelink, H. G. M. M., Pierce, L. J., & Feng, F. Y.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2898 · Cited by 168
Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine
Pasculli, B., Barbano, R., & Parrella, P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.007 · Cited by 174
Mechanisms of Genomic Instability in Breast Cancer
Duijf, P. H. G., Nanayakkara, D. M., Nones, K., Srihari, S., Kalimutho, M., & Khanna, K. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.004 · Cited by 171
TP53Mutations in Breast and Ovarian CancerPreprint
Silwal‐Pandit, L., Langerød, A., & Børresen‐Dale, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026252 · Cited by 177
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
Large-scale profiling of microRNAs for The Cancer Genome Atlas
Chu, A., Robertson, G., Brooks, D., Mungall, A. J. J., Birol, İ., Coope, R., Ma, Y. P., Jones, S. J. M., & Marra, M. A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv808 · Cited by 171
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers
Wang, Q., Jia, P., Li, F., Chen, H., Ji, H., Hucks, D., Dahlman, K. B., Pao, W. J., & Zhao, Z. (2013) · Genome Medicine · doi:10.1186/gm495 · Cited by 167
Fu, X., Jeselsohn, R. M., Pereira, R., Hollingsworth, E. F., Creighton, C. J., Li, F., Shea, M. J., Nardone, A., Angelis, C. D., Heiser, L. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612835113 · Cited by 172
Overview of the relevance of PI3K pathway in HR-positive breast cancer
Vasan, N., Toska, E., & Scaltriti, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz281 · Cited by 170
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Collaborators, G. S., Fachal, L., Collaborators, E., KConFab Investigators, HEBON Investigators, ABCTB Investigators, Aschard, H., Beesley, J., Barnes, D. R., Allen, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0537-1 · Cited by 168
Goel, H. L., Pursell, B. M., Chang, C., Shaw, L. M., Mao, J., Simin, K. J., Kumar, P., Kooi, C. W. V., Shultz, L. D., Greiner, D. L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202078 · Cited by 171
André, F., Hurvitz, S. A., Fasolo, A., Tseng, L., Jérusalem, G., Wilks, S. T., O'Regan, R. M., Isaacs, C. J., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 167
Damelin, M. I., Bankovich, A. J., Bernstein, J., Lucas, J., Chen, L., Williams, S. A., Park, A., Aguilar, J., Ernstoff, E., Charati, M. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2611 · Cited by 166
Recent progress in mass spectrometry proteomics for biomedical research
Li, X., Wang, W., & Chen, J. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9175-2 · Cited by 176
Wu, T.-C., Xu, K., Martínek, J., Young, R. R., Banchereau, R., George, J., Turner, J., Kim, K. I., Zurawski, S., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0413 · Cited by 168
Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., Gao, D., Delaidelli, A., Kyle, A. H., Baker, J. H. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0657 · Cited by 168
Pleasance, E., Titmuss, E., Williamson, L., Kwan, H., Culibrk, L., Stutheit-Zhao, E. Y., Dixon, K., Fan, K. Y., Bowlby, R., Jones, M. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0050-6 · Cited by 174
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
